The power of Zepbound

Is there anything that weight-loss drugs can't do? Zepbound will now be used in a trial in the UK to see if it combats unemployment. Eli Lilly will invest £279 million ($364 million) to help tackle Britain's significant health challenges.

The five-year trial in the Manchester area will explore how weight-loss drugs impact "participants' employment status and sick days from work".

It makes sense when you consider that the UK has a stubbornly high rate of economic inactivity, defined as those neither working nor looking for a job.

Almost a third of unemployment claims and NHS visits are attributed to long-term sickness, including pre-existing health conditions, such as obesity, and obesity-linked co-morbidities.

Get slim, get healthy, get back to work.